The civic record
Read. Follow. Verify.Idaho House Bill 530 caps out-of-pocket costs for oral cancer medications
Last action · March 25, 2026: Take bill off General Orders; referred to Business
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
Idaho House Bill 530 requires s covering FDA-approved s to ensure that out-of-pocket costs for oral cancer drugs do not exceed $250 per 30-day supply, or that their cost-sharing requirements are no higher than injected or intravenous treatments, effective July 1, 2026.
Patients taking oral chemotherapy or other prescribed cancer drugs gain financial protections that limit monthly out-of-pocket expenses, altering how health insurers structure cost-sharing for cancer treatments.
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
Health benefit plan enrollees
Enrollees prescribed oral anticancer medications experience capped monthly out-of-pocket expenses or cost-sharing parity with intravenous treatments.
Health insurers
Health benefit plans must adjust coverage structures to ensure oral anticancer drug copayments, deductibles, or coinsurance meet parity or dollar-cap requirements without increasing other anticancer cost-sharing.
Key Facts
- Establishes Section 41-1854, Idaho Code, regarding anticancer medication coverage under health benefit plans.
- Defines anticancer medication as a drug or biologic used to kill, slow, or prevent cancer cell growth administered orally, intravenously, or by injection.
- Requires health benefit plans covering FDA-approved anticancer medications to ensure copayment, deductible, or coinsurance for oral medications is no higher than for injected or IV treatments.
- Alternatively limits out-of-pocket costs for an orally administered anticancer medication to a maximum of $250 per 30-day supply.
Show all 6 facts
- Prohibits health plans from complying with cost caps by increasing cost-sharing amounts for other anticancer medications or reclassifying benefits.
- States that a health benefit plan is not required to classify anticancer medications as a medical benefit.
Frequently Asked Questions
What is the maximum out-of-pocket cost allowed for oral anticancer medications under this bill?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · in House committee.
Procedural history
8 actions- Mar 25, 2026CommitteeTake bill off General Orders; referred to Business
- Mar 6, 2026Retained on General Orders
- Feb 27, 2026Retained on General Orders
- Feb 13, 2026U.C. to be placed on General Orders, no objection
- Feb 13, 2026Read second time; Filed for Third Reading
- Feb 12, 2026Reported out of Committee with Do Pass Recommendation, Filed for Second Reading
Show 2 earlier actions
- Jan 27, 2026CommitteeReported Printed and Referred to Business
- Jan 26, 2026IntroducedIntroduced, read first time, referred to JRA for Printing
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Connected Entities
Sources
legislature.idaho.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 75)
- Controversy20Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools